To detect obesity medication using AI, Lilly has signed a $ 1.3 billion contract with Superluminal

Pharmaceutical Giant ELI Lilly has signed a $ 1.3 billion contract with Superluminal Medicines, which aims to discover and develop small molecular drugs for the treatment of obesity and other cardiometabolic diseases using artificial intelligence. Reuters report this information.